BioCardia’s FDA Accepts Helix Pre-Submission, Q2 Review Scheduled
FDA accepted BioCardia’s pre-submission package for its Helix Transendocardial Delivery Catheter, with substantive review and meeting scheduled for early Q2. CDRH, in consultation with CBER, acknowledges the CardiAMP Breakthrough Designation, potentially accelerating intramyocardial delivery system clearance and aiding CardiAMP therapy approval.
1. FDA Acceptance of Helix Pre-Submission
BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, marking the formal start of the regulatory review process. A substantive review and a meeting with FDA officials are slated for early Q2, advancing the device toward potential marketing clearance.
2. Review Process Led by CDRH and CBER
The FDA Center for Devices and Radiological Health will lead the review in consultation with the Center for Biological Evaluation and Research, reflecting Helix’s dual device and cell therapy applications. Recent preliminary meetings with both centers have outlined review pathways and underscored the CBER-enabled CardiAMP Breakthrough Designation tied to Helix.
3. Implications for CardiAMP Therapy and Business
Marketing clearance of Helix would provide the first FDA-approved minimally invasive catheter for intramyocardial delivery, enhancing the broader field of cardiac cell, gene, and protein therapeutics. Successful review could expedite approval of BioCardia’s CardiAMP cell therapy for ischemic heart failure and strengthen the company’s position as a biotherapeutic delivery partner.